Preterm Premature Rupture of Membranes Clinical Trial
Official title:
Magnesium Sulfate Versus Placebo for Tocolysis in Preterm Premature Rupture of Membranes
Study compares the outcomes of women between 26 and 32 wks gestation with rupture of membranes. Women randomized to receive tocolysis with magnesium sulfate x 48 hrs or placebo of saline IV x 48 hrs. Antibiotics and antenatal steroids given to both groups.
The majority of studies of the effectiveness of tocolysis with PPROM were in the 1980s prior
to the commmon usage of antenatal steroids and prophylactic maternal antibiotics. In most
studies, tocolysis was not attempted prior to the onset of labor in this group of women. The
ACOG Practice Bulletin of June 1998 concedes that the recommendation of tocolysis to permit
administration of steroids and maternal antibiotics is based primarily upon consensus, not
consistent scientific evidence.
The purpose of this study, which will randomize 128 subjects to tocolysis or no tocolysis,
is to prospectively assess whether short term (48 hr) tocolysis affords benefit to women and
babies between 26 and 32 weeks gestation with PPROM.
Subjects will be enrolled at 1-2 high risk hospitals in Chattanooga and Knoxville. All
English and Spanish speaking women 18-45 years with PPROM and cervical dilation <4 will be
eligible. Women with suspected intrauterine infection, positive fetal lung maturity, or > 6
hours tocolysis at time of admission will be excluded.
Both groups of women will receive continuous fetal monitoring, antibiotics, and antenatal
steroids (if not previously administered). Both groups will be evaluated every 2-4 hours for
fetal and maternal well being. Both groups will receive IVF at 125cc/hr, and the treatment
group will be loaded with 4 grams of magnesium sulfate and receive maintainence dose of 2
grams/hr x 48 hrs.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01431248 -
PPROM Erythromycin Versus Azithromycin
|
N/A | |
Active, not recruiting |
NCT04588220 -
Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM
|
||
Completed |
NCT02314728 -
Cervical Ripening in Premature Rupture of Membranes
|
N/A | |
Not yet recruiting |
NCT01152528 -
Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery
|
Phase 3 | |
Completed |
NCT02702297 -
Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes
|
||
Not yet recruiting |
NCT02635451 -
The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes
|
N/A | |
Completed |
NCT01266928 -
Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study
|
Phase 3 | |
Active, not recruiting |
NCT04532021 -
Matrix Metalloproteinase 14, Neopterin, and Orosomucoid 1 Levels in PPROM
|
||
Recruiting |
NCT02548013 -
Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management
|
N/A | |
Recruiting |
NCT01584323 -
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
|
N/A | |
Recruiting |
NCT00466128 -
Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)
|
Phase 2 |